Monday, November 17, 2014 1:49:03 AM
ABOUT FENNEC PHARMACEUTICALS
Fennec Pharmaceuticals is a small stage biotechnology company focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients.
WHY FENNEC?
Originating in Saharan North Africa, the fennec fox is the smallest of the foxes and uniquely adapted to high temperatures and low water environments. It has distinctively large ears which dissipate heat and provide very sensitive hearing. These qualities of adaptability and resourcefulness led us to adopt the fox with the big ears as our new name and logo.
Children undergoing chemotherapy are going through an extraordinarily challenging time and the loss of hearing only compounds the difficulty. Fennec Pharma, named after that resourceful and determined fennec fox hopes that STS will allow these children to keep their hearing and prevent permanent disability. As the company refocuses on this mission, it seemed appropriate to adopt the fox with the big ears as our new name and logo.
Many have asked what the fox says. We at Fennec are far more interested in “Who can the fox help?” This is a rough desert for a child to walk across. We’d like to give them a helping hand, er, paw.
Recent FENC News
- Fennec Pharmaceuticals Announces Management Change • GlobeNewswire Inc. • 07/01/2024 10:00:00 AM
- Fennec Announces Results of Annual Meeting • GlobeNewswire Inc. • 06/25/2024 08:35:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 10:21:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 09:12:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 08:29:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:05:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:05:13 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:24:27 PM
- Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/14/2024 10:03:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/13/2024 08:42:27 PM
- Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 10:15:00 PM
- Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/21/2024 10:00:00 AM
- Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024 • GlobeNewswire Inc. • 03/19/2024 10:01:00 AM
- Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand • PR Newswire (US) • 03/18/2024 07:00:00 AM
- Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand • GlobeNewswire Inc. • 03/18/2024 01:00:00 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/06/2024 09:07:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:04:59 PM
- Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results • GlobeNewswire Inc. • 02/29/2024 12:04:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 03:47:17 PM
- FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin • GlobeNewswire Inc. • 02/01/2024 10:55:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 10:24:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/05/2024 09:45:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/04/2024 09:42:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 09:30:19 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM